Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Clinical trial NCT01204476 · COMPLETED

Trial details

NCT number: NCT01204476
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Gastrin-Producing Neuroendocrine Tumor Lung Carcinoid Tumor Metastatic Digestive System Neuroendocrine Tumor G1 Pancreatic Glucagonoma Pancreatic Insulinoma Pancreatic Polypeptide Tumor Paraganglioma Recurrent Digestive System Neuroendocrine Tumor G1 Recurrent Merkel Cell Carcinoma Recurrent Pancreatic Neuroendocrine Carcinoma Regional Digestive System Neuroendocrine Tumor G1 Somatostatin-Producing Neuroendocrine Tumor

Start date: 2010-10-01
Primary completion: 2014-07-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.